Equities researchers at StockNews.com started coverage on shares of iBio (NYSE:IBIO – Get Free Report) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.
iBio Stock Down 3.4 %
IBIO opened at $1.71 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a 12-month low of $1.02 and a 12-month high of $27.80.
iBio (NYSE:IBIO – Get Free Report) last issued its earnings results on Friday, February 9th. The company reported ($2.42) EPS for the quarter.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- Best Aerospace Stocks Investing
- Comprehensive Analysis of PayPal Stock
- About the Markup Calculator
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- What is the Dogs of the Dow Strategy? Overview and Examples
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
